PPLPHARMA · NSE
Not in active coverage. Cited reporting has mentioned Piramal Pharma, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Piramal Pharma's Morpeth facility in the UK received seven observations following a US FDA inspection conducted from September 3 to 11, 2026.
Piramal Pharma Ltd announced that the US Food and Drug Administration (FDA) issued a Form-483 with seven observations after a Good Manufacturing Practices (GMP) inspection of its Morpeth, UK facility.
Piramal Pharma Ltd is seeing increased customer interest in its contract development and manufacturing business following US President Donald Trump’s recent tariff threats aimed at discouraging medicine imports.
Piramal Pharma, Anthem Biosciences, and Cohance Lifesciences are listed Indian CDMO companies with disclosed ADC-related capabilities, programmes, and investments.
Piramal Pharma Limited announced its standalone and consolidated unaudited financial results for the quarter ended 30 June 2026, with consolidated revenue from operations of ₹2,270 crores, representing 17% growth compared to ₹1,934 crores in the same quarter of the previous year.
Reported Consolidated quarterly numbers for Piramal Pharma are: Net Sales at Rs 2,269.92 crore in June 2026 up 17.39% from Rs. 1,933.71 crore in June 2025. Quarterly Net Loss at Rs. 69.39 crore in June 2026 up 15.07% from Rs. 81.70 crore in June 2025. EBITDA stands at Rs. 284.61 crore in June 2026…
This page lists where cited reporting has mentioned Piramal Pharma. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.